BioTuesdays

Category - Markets

Cingulate Logo
Markets

Maxim starts Cingulate at buy; PT $3

Maxim Group launched coverage of Cingulate (NASDAQ:CING) with a “buy” rating and price target of $3. The stock closed at 69 cents on Nov. 21. Cingulate is a Phase 3-ready company developing multiple therapies for...

November 22, 2022
Trevi Logo
Markets

SVB starts Trevi Therapeutics at OP; PT $6

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...

November 22, 2022
Cullinan Logo
Markets

BTIG starts Cullinan Oncology at buy; PT $20

BTIG initiated coverage of Cullinan Oncology (NASDAQ:CGEM) with a “buy” rating and price target of $20, citing a burgeoning pipeline and unique biology that could open avenues for a broad range of opportunities. The...

November 21, 2022
Provention Bio Logo
Markets

Cantor ups Provention Bio PT on FDA T1D approval

Cantor Fitzgerald raised its price target for Provention Bio (NASDAQ:PRVB) to $16 from $12 and maintained an “overweight” rating after the FDA approved teplizumab (brand name, TZIELD) to delay the onset of Type 1...

November 18, 2022
KemPharm
Markets

Cantor starts KemPharm at OW; PT $20

Cantor Fitzgerald initiated coverage of KemPharm (NASDAQ:KMPH) with an “overweight’ rating and a 12-month discounted cash flow-based price target of $20. The stock closed at $4.39 on Nov. 16. “We think KemPharm’s...

November 17, 2022
Theratechnologies
Markets

Cantor starts Theratechnologies at OW; PT $9

Cantor Fitzgerald launched coverage of Theratechnologies (NASDAQ:THTX) with an “overweight” rating and $9 price target. The stock closed at $1.88 on Nov. 16. “We believe the peak sales potential of Theratechnologies’...

November 17, 2022
Syros Logo
Markets

HCW ups Syros PT on optimism about AML data at ASH

H.C Wainwright raised its price target for Syros Pharmaceuticals (NASDAQ:SYRS) to $20 from $6, noting that the company’s tamibarotene “looks to shine during ASH ‘22” in December. The stock closed at $3.66 on Nov. 14...

November 15, 2022
Satsuma Pharmaceuticals
Markets

SVB cuts Satsuma to MP after negative SUMMIT data

SVB Securities downgraded Satsuma Pharmaceuticals (NASDAQ:STSA) to “market perform” from “outperform” and slashed its price target to $1 from $15 after the company reported negative data for the Phase 3 SUMMIT trial of...

November 15, 2022
Janux Logo
Markets

WB starts Janux Therapeutics at OP

William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...

November 14, 2022